These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 32338080)
1. Comparison of the effect of topical bevacizumab and sorafenib in experimental corneal neovascularization. Yildirim H; Aydemir O; Balbaba M; Özercan İH; İlhan N Cutan Ocul Toxicol; 2020 Sep; 39(3):223-228. PubMed ID: 32338080 [TBL] [Abstract][Full Text] [Related]
2. Effects of sunitinib and bevacizumab on VEGF and miRNA levels on corneal neovascularization. Cakmak H; Gokmen E; Bozkurt G; Kocaturk T; Ergin K Cutan Ocul Toxicol; 2018 Jun; 37(2):191-195. PubMed ID: 28874077 [TBL] [Abstract][Full Text] [Related]
3. Effect of topical motesanib in experimental corneal neovascularization model. Çelenk M; Yıldırım H; Tektemur A; Balbaba M; Erdağ M Int Ophthalmol; 2023 Aug; 43(8):2989-2997. PubMed ID: 36971928 [TBL] [Abstract][Full Text] [Related]
4. The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization. Eski MT; Teberik K; Oltulu P; Ankaralı H; Kaya M; Alpay M Hum Exp Toxicol; 2022; 41():9603271221084674. PubMed ID: 35465742 [TBL] [Abstract][Full Text] [Related]
5. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model. Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227 [TBL] [Abstract][Full Text] [Related]
6. [Vascular morphological and microdensity changes of corneal neovascularization induced by topical bevacizumab and sunitinib in an animal model]. Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Fernández-Sánchez L; Cuenca-Navarro N Arch Soc Esp Oftalmol; 2013 Dec; 88(12):473-81. PubMed ID: 24257257 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization. Ozdemir O; Altintas O; Altintas L; Ozkan B; Akdag C; Yüksel N Arq Bras Oftalmol; 2014 Aug; 77(4):209-13. PubMed ID: 25410169 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the Effects of Dovitinib and Bevacizumab on Reducing Neovascularization in an Experimental Rat Corneal Neovascularization Model. Sahan B; Ciftci F; Eyuboglu S; Yaba A; Yilmaz B; Yalvac BI Cornea; 2019 Sep; 38(9):1161-1168. PubMed ID: 31180924 [TBL] [Abstract][Full Text] [Related]
9. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model. Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642 [TBL] [Abstract][Full Text] [Related]
10. Effects of Combined Photodynamic Therapy and Topical Bevacizumab Treatment on Corneal Neovascularization in Rabbits. Kim RY; Chung SK; Kim MS; Ra H Cornea; 2016 Dec; 35(12):1615-1620. PubMed ID: 27684458 [TBL] [Abstract][Full Text] [Related]
11. Effects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization. Ozdemir O; Altintas O; Altintas L; Yildiz DK; Sener E; Caglar Y Can J Ophthalmol; 2013 Apr; 48(2):115-20. PubMed ID: 23561605 [TBL] [Abstract][Full Text] [Related]
12. The effect of bevacizumab on corneal neovascularization in rabbits. Kim WJ; Jeong HO; Chung SK Korean J Ophthalmol; 2010 Aug; 24(4):230-6. PubMed ID: 20714387 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model. Sella R; Gal-Or O; Livny E; Dachbash M; Nisgav Y; Weinberger D; Livnat T; Bahar I Exp Eye Res; 2016 May; 146():224-232. PubMed ID: 27020759 [TBL] [Abstract][Full Text] [Related]
14. Effect of bevacizumab on corneal neovascularization in experimental rabbit model. Ahmed A; Berati H; Nalan A; Aylin S Clin Exp Ophthalmol; 2009 Sep; 37(7):730-6. PubMed ID: 19788671 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Kim TI; Kim SW; Kim S; Kim T; Kim EK Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666 [TBL] [Abstract][Full Text] [Related]
16. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Habot-Wilner Z; Barequet IS; Ivanir Y; Moisseiev J; Rosner M Acta Ophthalmol; 2010 Dec; 88(8):862-7. PubMed ID: 19549103 [TBL] [Abstract][Full Text] [Related]
17. Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization. Kaya MK; Demir T; Bulut H; Akpolat N; Turgut B Clin Exp Ophthalmol; 2015 Jul; 43(5):449-57. PubMed ID: 25640924 [TBL] [Abstract][Full Text] [Related]
18. The inhibitory effects of trastuzumab on corneal neovascularization. Güler M; Yilmaz T; Ozercan I; Elkiran T Am J Ophthalmol; 2009 Apr; 147(4):703-708.e2. PubMed ID: 19054498 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123 [TBL] [Abstract][Full Text] [Related]
20. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats. Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]